[1] Qingyan BO, et al. Method of treating virus infection using a tlr7 agonist. Patent WO2021130195A1.
[2] Jiang Q, et al. Using exploratory pharmacokinetic and pharmacodynamic analyses to predict the probability of flu‐like symptoms in healthy volunteers and patients with chronic hepatitis B treated with the toll‐like receptor 7 agonist ruzotolimod[J]. Clinical and Translational Science, 2024, 17(8): e13896. DOI:
10.1111/cts.13896[3] Croasdell G. European Association for the Study of the Liver-53rd International Liver Congress. Paris, France-April 11-15, 2018. Drugs of the Future, 2018, 43(7).
[4] Wildum S, et al. Toll-Like Receptor 7 Agonist RG7854 Mediates Therapeutic Efficacy and Seroconversion in Woodchucks With Chronic Hepatitis B. Front Immunol. 2022 May 23;13:884113. DOI:
10.3389/fimmu.2022.884113